This site is intended for Healthcare Professionals only.

BREAKING: CMA fines Pfizer and Flynn £70 million for inflating price of anti-epilepsy drug by 2,600pc


Share post:

Britain’s competition watchdog has fined pharmaceutical companies Pfizer and Flynn £63 million and £6.7 million respectively for allegedly breaking competition law and illegally profiting from the sale of an anti-epilepsy drug.

The Competition and Markets Authority (CMA) found that the two companies colluded to sell phenytoin sodium capsules, previously known as Epanutin, at “unfairly high prices” for over four over years between 2012 and 2016.

The annual costs of the capsules for the NHS increased from £2 million in 2012 to approximately £50 million the following year.

CMA has accused Pfizer of charging, over four years, prices between 780 per cent and 1,600 per cent higher than what was fixed previously for the medicine used to prevent life-threatening epileptic seizures.

Pfizer supplied the drug to Flynn, which then sold the capsules on to wholesalers and pharmacies at a price between 2,300 per cent and 2,600 per cent higher than the prices previously charged by Pfizer.

CMA explained that Pfizer and Flynn first “de-branded” the drug which allowed them “to set prices at their discretion” as it was no longer subject to any price regulation.

The NHS had no choice but to pay the inflated final price because Pfizer and Flynn were the dominant suppliers of the drug in the UK market at the time.

Andrea Coscelli, chief executive of the CMA, said: “Phenytoin is an essential drug relied on daily by thousands of people throughout the UK to prevent life-threatening epileptic seizures. These firms illegally exploited their dominant positions to charge the NHS excessive prices and make more money for themselves… Such behavior will not be tolerated, and the companies must now face the consequences of their illegal action.”

The CMA in 2016 had fined Pfizer and Flynn about £90 million for inflating prices for Epanutin by as much as 2,600 to 67.50 pounds for a 100mg pack before the companies won a 2018 appeal against the penalty.

The Competition Appeal Tribunal had referred the matter back to the CMA, which in August 2021 stuck to its view that the two firms broke the law.

Both Pfizer and Flynn Pharma said they intend to appeal the CMA decision.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...